In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study

Johansson, Anna L. V.; Trewin, Cassia B.; Fredriksson, Irma; Reinertsen, Kristin V.; Russnes, Hege; Ursin, Giske

doi:10.1186/s13058-021-01393-z

Table 1 Clinicopathologic characteristics by IHC subtype for women with invasive breast cancer, Norway 2005–2015 age 20–74 years

From: In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study

IHC subtype	ER+PR+HER2−		ER+PR−HER2−		ER+PR+HER2+		ER+PR−HER2+		ER−PR−HER2+ (HER2pos)		ER−PR−HER2− (TNBC)		Missing^a		Total
IHC subtype	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Total	13,010	100	3036	100	1424	100	834	100	1103	100	2114	100	2616	100	24,137	100.0
Age
20–39	545	4.2	132	4.3	180	12.6	69	8.3	121	11.0	288	13.6	159	6.1	1494	6.2
40–49	2799	21.5	371	12.2	445	31.3	163	19.5	247	22.4	467	22.1	480	18.3	4972	20.6
50–59	4112	31.6	1015	33.4	361	25.4	305	36.6	371	33.6	639	30.2	883	33.8	7686	31.8
60–69	4489	34.5	1212	39.9	360	25.3	243	29.1	286	25.9	557	26.3	884	33.8	8031	33.3
70–74	1065	8.2	306	10.1	78	5.5	54	6.5	78	7.1	163	7.7	210	8.0	1954	8.1
Year
2005–2008	3865	29.7	987	32.5	416	29.2	224	26.9	365	33.1	736	34.8	1508	57.6	8101	33.6
2009–2012	4708	36.2	1035	34.1	578	40.6	316	37.9	402	36.4	728	34.4	890	34.0	8657	35.9
2013–2015	4437	34.1	1014	33.4	430	30.2	294	35.3	336	30.5	650	30.7	218	8.3	7379	30.6
Grade
I: low	3608	29.3	614	21.7	79	5.9	36	4.8	15	1.5	30	1.5	494	23.2	4876	21.9
II: intermediate	6849	55.6	1459	51.6	666	50.2	331	43.8	244	24.9	340	17.5	968	45.4	10,857	48.7
III: high	1860	15.1	752	26.6	583	43.9	388	51.4	719	73.5	1571	80.9	671	31.5	6544	29.4
Missing	693		211		96		79		125		173		483		1860
Ki67^b
0–14.9%	2173	37.2	388	30.5	75	14.3	22	6.4	15	4.3	37	4.7	94	30.8	2804	29.7
15.0–30.0%	2138	36.6	384	30.2	128	24.3	106	30.9	68	19.7	64	8.1	93	30.5	2981	31.6
30.1–100%	1531	26.2	501	39.4	323	61.4	215	62.7	263	76.0	692	87.3	118	38.7	3643	38.6
Missing 2011–2015	1110		293		207		142		186		246		299		2483
Missing 2005–2010															12,226
Tumour size
pT1, 0–20 mm	8407	72.2	1735	66.9	718	62.3	372	58.5	434	53.5	929	54.6	1415	69.9	14,010	68.2
pT2, 21–50 mm	2932	25.2	778	30.0	400	34.7	242	38.1	329	40.6	725	42.6	538	26.6	5944	28.9
pT3, > 50 mm	186	1.6	55	2.1	19	1.6	12	1.9	22	2.7	23	1.4	29	1.4	346	1.7
pT4: spread, any size	115	1.0	24	0.9	16	1.4	10	1.6	26	3.2	23	1.4	43	2.1	257	1.3
Missing	1370		444		271		198		292		414		591		3580
Nodal status
pN0, 0 nodes+	8141	67.4	1816	65.2	716	55.3	376	50.9	441	45.3	1196	63.1	1503	64.3	14,189	64.2
pN1, 1–3 nodes+	3333	27.6	819	29.4	479	37.0	282	38.2	424	43.5	599	31.6	745	31.9	6681	30.2
pN2, 4–9 nodes+	413	3.4	90	3.2	73	5.6	55	7.4	67	6.9	62	3.3	60	2.6	820	3.7
pN3, 10+ nodes+	187	1.5	60	2.2	27	2.1	26	3.5	42	4.3	39	2.1	28	1.2	409	1.9
Missing	936		251		129		95		129		218		280		2038
TNM stage
I	6619	53.0	1406	48.5	519	38.2	266	33.8	296	28.4	730	36.8	1236	50.0	11,072	48.1
II	4519	36.2	1117	38.6	589	43.3	324	41.2	465	44.6	953	48.1	887	35.9	8854	38.5
III	1056	8.5	285	9.8	185	13.6	144	18.3	225	21.6	234	11.8	225	9.1	2354	10.2
IV	287	2.3	88	3.0	66	4.9	53	6.7	56	5.4	65	3.3	123	5.0	738	3.2
Missing	529		140		65		47		61		132		145		1119

^aMissing on any of ER/PR/HER2 (n = 2351), ER−PR+HER2− (n = 176), or ER−PR+HER2+ (n = 89)
^bKi67 only available years 2011–2015

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us